Filter news by date News Tags - Any -- Any -News storyPress release Month MonthMonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year YearYear20252024202320222021202020192018201720162015201420132012201120102009200820072006 Apply 3 . 14 . 2025 Press release Galderma successfully placed an inaugural EUR 500 million single tranche Eurobond and new dual tranche CHF 435 million CHF bonds 3 . 6 . 2025 Press release Galderma delivers 2024 record net sales of 4.410 billion USD, up 9.3% year-on-year at constant currency1, and record Core EBITDA of 1.031 billion USD, while preparing to accelerate its growth trajectory into 2025 and beyond 3 . 3 . 2025 Press release AAD 2025: Galderma to present extensive updates from across its dermatology portfolio, demonstrating its category leadership and strong momentum 3 . 2 . 2025 News story AAD 2025: Galderma’s Scientific Presentations 2 . 18 . 2025 Press release Galderma’s Nemluvio® (nemolizumab) granted marketing authorization in the United Kingdom and Switzerland for moderate-to-severe atopic dermatitis and prurigo nodularis 2 . 14 . 2025 Press release Galderma’s Nemluvio® (nemolizumab) approved in the European Union for moderate-to-severe atopic dermatitis and prurigo nodularis 1 . 31 . 2025 Press release IMCAS 2025: New Galderma phase IIIb data reinforce rapid onset and long-lasting aesthetic improvement with RelabotulinumtoxinA (Relfydess™) 1 . 30 . 2025 Press release Galderma demonstrates Injectable Aesthetics leadership in medication-driven weight loss with new research and first international consensus-based guidelines 1 . 23 . 2025 Press release IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership 1 . 23 . 2025 News story IMCAS 2025: Galderma’s Scientific Presentations 1 . 14 . 2025 Press release Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss 12 . 19 . 2024 News story Beyond trends: equipping the aesthetics community for what’s NEXT 12 . 14 . 2024 Press release Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis Pagination Next page Next Page